Prostate cancer (PCa) remains the most prevalent cancer among men and the second leading cause of cancer-related deaths worldwide. Early diagnosis is crucial as it opens up various treatment options with curative intent. Recent advancements confirm that radiotherapy (RT), particularly through modern techniques like stereotactic body RT (SBRT) and single-dose RT (SDRT), is a safe and effective treatment for both localized and advanced PCa. This manuscript reviews the evolution and current state of primary prostate SDRT, focusing on its benefits and limitations. SDRT offers advantages such as reduced treatment time and enhanced patient convenience, showing promising efficacy and safety, especially for low- and intermediate-risk PCa. Challenges include controlling intrafraction variability and organ motion, as well as minimizing urethral toxicity. Next-generation imaging and MR-guided RT are improving treatment accuracy. While SDRT shows potential for cost-effective PCa treatment, further research is needed to address its limitations and refine its clinical application.
前列腺癌（PCa）仍是全球男性中最常见的癌症，也是癌症相关死亡的第二大原因。早期诊断至关重要，因为它为治愈性治疗提供了多种选择。最新进展证实，放射治疗（RT），特别是通过立体定向体部放疗（SBRT）和单次放疗（SDRT）等现代技术，对于局限性和晚期前列腺癌都是一种安全有效的治疗方法。本文综述了前列腺癌单次放疗的发展历程和现状，重点探讨其优势与局限性。单次放疗具有缩短治疗时间、提高患者便利性等优点，尤其在低危和中危前列腺癌中显示出良好的疗效和安全性。面临的挑战包括控制分次内变异性和器官运动，以及减少尿道毒性。新一代成像技术和磁共振引导放疗正在提高治疗精确性。虽然单次放疗显示出作为前列腺癌经济有效治疗手段的潜力，但仍需进一步研究以解决其局限性并优化临床应用。
Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
肿瘤(癌症)患者之家